- Home
- RRX vs CORT Comparison
RRX vs CORT Comparison
Compare RRX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRX
- CORT
- Stock Information
- Founded
- RRX 1955
- CORT 1998
- Country
- RRX United States
- CORT United States
- Employees
- RRX N/A
- CORT N/A
- Industry
- RRX
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- RRX
- CORT Health Care
- Exchange
- RRX Nasdaq
- CORT Nasdaq
- Market Cap
- RRX 9.6B
- CORT 8.8B
- IPO Year
- RRX 1987
- CORT N/A
- Fundamental
- Price
- RRX $144.47
- CORT $89.51
- Analyst Decision
- RRX Strong Buy
- CORT Strong Buy
- Analyst Count
- RRX 9
- CORT 4
- Target Price
- RRX $175.33
- CORT $139.00
- AVG Volume (30 Days)
- RRX 741.2K
- CORT 917.9K
- Earning Date
- RRX 11-03-2025
- CORT 10-29-2025
- Dividend Yield
- RRX 0.97%
- CORT N/A
- EPS Growth
- RRX N/A
- CORT N/A
- EPS
- RRX 3.76
- CORT 1.11
- Revenue
- RRX $5,852,700,000.00
- CORT $716,080,000.00
- Revenue This Year
- RRX N/A
- CORT $30.77
- Revenue Next Year
- RRX $3.91
- CORT $37.75
- P/E Ratio
- RRX $38.28
- CORT $81.04
- Revenue Growth
- RRX N/A
- CORT 25.71
- 52 Week Low
- RRX $90.56
- CORT $42.01
- 52 Week High
- RRX $185.28
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- RRX 50.24
- CORT 77.49
- Support Level
- RRX $139.90
- CORT $82.70
- Resistance Level
- RRX $145.19
- CORT $90.71
- Average True Range (ATR)
- RRX 4.37
- CORT 2.60
- MACD
- RRX 0.64
- CORT 0.78
- Stochastic Oscillator
- RRX 41.73
- CORT 94.53
About RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.